1461088606-d52f7ebf-6397-4d78-ae5e-69a3bbbfbd9a

1-12. (canceled)
13. A polypeptide comprising a sequence selected from the group consisting of:
(a) a Glial-cell Derived Neurotrophic Factor Receptor a (GDNFR\u03b1) extracellular domain (ECD) amino acid sequence;
(b) an allelic variant or mammalian homolog of (a);
(c) a sequence encoded by nucleic acid which hybridizes under stringent conditions to a nucleic acid encoding (a) or (b); and
(d) a sequence derived from (a) or (b) by substitution, deletion, or addition of one or several amino acids in the amino acid sequence of (a) or (b).
14. The polypeptide of claim 13, comprising the amino acid sequence of GDNFR\u03b1 ECD from SEQ ID NO 2.
15. The polypeptide of claim 14, comprising the amino acid sequence of mature GDNFR\u03b1 from SEQ ID NO 2.
16. The polypeptide of claim 15, which specifically binds Glial-cell Derived Neurotrophic Factor (GDNF).
17. The polypeptide of claim 16, which is conjugated with, or fused to, a molecule which increases the serum half-life thereof.
18. The polypeptide of claim 13 that is soluble GDNFR\u03b1.
19. A composition comprising the polypeptide of claim 13 and a physiologically acceptable carrier.
20. The polypeptide of claim 13 that is chimeric GDNFR\u03b1.
21. The chimeric GDNFR\u03b1 of claim 20, comprising a GDNFR\u03b1 amino acid sequence fused to an immunoglobulin sequence.
22. The chimeric GDNFR\u03b1 of claim 20, comprising a GDNFR\u03b1 amino acid sequence fused to an epitope tag sequence.
23. A method for identifying a molecule which binds to the GDNFR\u03b1, comprising exposing the GDNFR\u03b1 to the molecule suspected of binding thereto and determining binding of the molecule to the GDNFR\u03b1.
24. The method of claim 23, wherein the GDNFR\u03b1 is soluble GDNFR\u03b1.
25. A method for identifying a molecule which activates GDNFR\u03b1, comprising exposing the GDNFR\u03b1 to a molecule suspected of being capable of activating GDNFR\u03b1 and measuring activation of GDNFR\u03b1.
26. A method for purifying a molecule which binds to GDNFR\u03b1, comprising adsorbing the molecule to GDNFR\u03b1 immobilized on a solid phase and recovering the molecule from the immobilized GDNFR\u03b1.
27. The method of claim 26 wherein the GDNFR\u03b1 is chimeric GDNFR\u03b1, comprising a fusion of a GDNFR\u03b1 extracellular domain sequence to an immunoglobulin constant domain sequence.
28. An antibody that specifically binds to GDNFR\u03b1 of claim 13.
29. The antibody of claim 28, which is a monoclonal antibody.
30. A composition comprising the antibody of claim 29 and a physiologically acceptable carrier.
31. The composition of claim 30 further comprising a cytokine or a neurotrophic factor.
32. A method for activating GDNFR\u03b1, comprising exposing GDNFR\u03b1 to an amount of an agonist antibody of claim 28 which is effective for activating GDNFR\u03b1.
33. A method for modulating a physiological response of a cell to GDNF, comprising contacting the cell with an amount of a GDNFR\u03b1 effective for modulating the response of the cell to GDNF.
34. A method for determining the presence of GDNFR\u03b1, comprising exposing a test sample suspected of containing the GDNFR\u03b1 to the antibody of claim 28 and determining binding of said antibody to the test sample.
35. A nucleic acid molecule comprising a nucleic acid sequence encoding GDNFR\u03b1 of claim 13.
36. The nucleic acid molecule of claim 35, further comprising a promoter operably linked to the nucleic acid molecule.
37. The nucleic acid molecule of claim 35, wherein the nucleic acid sequence encodes GDNFR\u03b1 ECD.
38. The nucleic acid molecule of claim 35, wherein the nucleic acid sequence encodes chimeric GDNFR\u03b1.
39. An expression vector comprising the nucleic acid molecule of claim 35 operably linked to control sequences recognized by a host cell transformed with the vector.
40. A host cell comprising the vector of claim 39.
41. A nucleic acid comprising a nucleic acid sequence of at least 18 contiguous nucleotides from GDNFR\u03b1.
42. A process of using a nucleic acid molecule encoding GDNFR\u03b1 to effect production of GDNFR\u03b1, comprising culturing the host cell of claim 40 under conditions allowing expression of GDNFR\u03b1.
43. The process of claim 42 further comprising recovering the GDNFR\u03b1 from the host cell culture.
44. A non-human, transgenic animal which contains cells that express nucleic acid encoding GDNFR\u03b1 polypeptide.
45. A non-human, knockout animal which contains cells having an altered GDNFR\u03b1 gene.
46. A method of treating kidney disease, comprising administering to a patient in need of treatment a therapeutically effective amount of GDNF or GDNF agonist.
47. The method of claim 46, wherein the GDNF is human GDNF.
48. The method of claim 46, further comprising administration of GDNFR\u03b1.
49. The method of claim 46, wherein the kidney disease is associated with glomerulonephritis.
50. A method of treating an enteric nervous system-related disorder, comprising administering to a patient in need of such treatment a therapeutically effective amount of GDNF or GDNF agonist.
51. The method of claim 50, wherein the GDNF is human GDNF.
52. The method of claim 50, further comprising administration of GDNFR\u03b1.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An electromagnetic tracking system comprising:
at least one transmitter assembly including one or more transmitter coils;
at least one receiver assembly communicating with and receiving signals from the at least one transmitter assembly, the at least one receiver assembly including at least one ferrite rod antenna; and
electronics coupled to and communicating with the at least one transmitter assembly and the at least one receiver assembly for calculating the position and orientation of an object to be tracked.
2. The electromagnetic tracking system of claim 1, wherein the one or more ferrite rod antenna is configured to provide a low profile electromagnetic receiver coil array.
3. The electromagnetic tracking system of claim 1, wherein the object to be tracked is a medical device, implant or instrument.
4. The electromagnetic tracking system of claim 1, wherein the at least one electromagnetic transmitter assembly is attached to a medical device, implant or instrument to be tracked and the at least one electromagnetic receiver assembly is positioned within at least one electromagnetic field generated by the at least one electromagnetic transmitter assembly to track the position and orientation of the medical device, implant or instrument.
5. The electromagnetic tracking system of claim 1, wherein the at least one electromagnetic receiver assembly 14 may be attached to a medical device, implant or instrument to be tracked and the at least one electromagnetic transmitter assembly 12 may generate at least one electromagnetic field to be received by the at least one electromagnetic receiver assembly to track the position and orientation of the medical device, implant or instrument.
6. The electromagnetic tracking system of claim 1, wherein the one or more ferrite rod antenna includes a ferrite rod with at least one turn of an electrically conductive coil wound around the ferrite rod.
7. The electromagnetic tracking system of claim 1, wherein the one or more ferrite rod antenna includes a ferrite rod with at least one turn of an electrically conductive coil wound around the ferrite rod and a capacitor coupled to the coil.
8. The electromagnetic tracking system of claim 1, wherein the one or more ferrite rod antenna is positioned on a plane.
9. The electromagnetic tracking system of claim 8, wherein the one or more ferrite rod antenna is positioned horizontally on the same plane.
10. The electromagnetic tracking system of claim 8, wherein the one or more ferrite rod antenna is positioned vertically above the plane.
11. The electromagnetic tracking system of claim 8, wherein the plane is an electrically conductive plane.
12. The electromagnetic tracking system of claim 8, wherein the plane is a printed circuit board.
13. The electromagnetic tracking system of claim 1, wherein the one or more transmitter coil is a ferrite rod antenna.
14. A receiver coil array for an electromagnetic tracking system comprising a plurality of ferrite rod antennas positioned on a plane at different locations, with different orientations, and pointing in different directions.
15. The receiver coil array of claim 14, wherein each ferrite rod antenna of the plurality of ferrite rod antennas includes a ferrite rod with at least one turn of an electrically conductive coil wound around the ferrite rod.
16. The receiver coil array of claim 14, wherein the plurality of ferrite rod antennas are horizontally arranged and attached to a plane.
17. The receiver coil array of claim 16, wherein the plane is a printed circuit board.
18. The receiver coil array of claim 14, wherein the plurality of ferrite rod antennas are horizontally arranged and attached to an electrically conducting plane.
19. The receiver coil array of claim 18, wherein the plane is a printed circuit board.
20. The receiver coil array of claim 14, wherein the plurality of ferrite rod antennas are vertically arranged and attached to a plane.
21. The receiver coil array of claim 20, wherein the plane is a printed circuit board.
22. The receiver coil array of claim 14, wherein the plurality of ferrite rod antennas are vertically arranged and attached to an electrically conducting plane.
23. The receiver coil array of claim 22, wherein the plane is a printed circuit board.
24. The receiver coil array of claim 14, wherein the plurality of ferrite rod antennas are all positioned on the same plane.
25. A transmitter coil array for an electromagnetic tracking system comprising at least one ferrite rod antenna.